


INTRODUCTION




Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria. During COVID-19 pandemic, the incidence of bacterial infection in hospitalized COVID-19 patients was high, especially those caused by multidrug-resistant Gram-negative bacteria such as *Pseudomonas aeruginosa*, an emerging multidrug-resistant global opportunistic pathogen, more commonly associated with respiratory infections in humans. The aim of this study was to typing *P. aeruginosa* strains (n=18) isolated from hospitalized patients during COVID-19 pandemic.

METHODOLOGY



July/2021 to March/2022
Rio de Janeiro/RJ

- 17 patients (11 males and seven females) with ages varying from 45 to 97 years
- 12 with COVID-19 co-infection, four only with *P. aeruginosa*, and two found during Hospital Infection Prevention and Control (HIPC) monitoring;
- Clinical specimens included tracheal secretion (n=9), urine (n=6), rectal swab (n=2), and oral swab (n=1).



RESULTS AND CONCLUSIONS

Thirteen FTIR profiles were obtained with a cut-off of 0.261, a ratio of 1.54 strain/profile (Figure 1). From the three clusters formed, the one that comprises IR13 profile had only COVID-19 co-infections strains from the same local, indicating that they possibly had the same common source. Strains from the IR11 cluster were isolated from HIPC samples and other locals, indicating that this clone may be present in the hospital environment. No correlation could be inferred from the two strains of the IR8 profile. Nine (50.0%) strains were susceptible to all antibiotics tested. No association between the AST and FTIR profiles was observed since resistance and susceptible strains were found in the same cluster. Considering the necessity to use broad-spectrum antibiotics in cases of *P. aeruginosa* infections, the resistance found to four classes of antimicrobial agents (β -lactam, cepheims, folate pathway antagonists, and fluoroquinolones) is worrisome. In conclusion, the FTIR seems to be an interesting tool for the evaluation of the clonality of *P. aeruginosa* and a helpful approach to understanding the epidemiology of this bacteria.




Figure 1. Dendrogram obtained by clustering the FTIR spectra of *P. aeruginosa* (n=18). The vertical dashed line represents the cut-off value. Patient identification, type of sample, local, VITEK®2 bionumber profile, and antimicrobial susceptibility profile are given for each strain. FTIR: Fourier-Transform Infrared Spectroscopy; TZP: piperacillin-tazobactam; FEP: cefepime; CAZ: ceftazidime; MEM: meropenem; GEN: gentamicin; CIP: ciprofloxacin; NOR: norfloxacin.

BIBLIOGRAFY

BrCAST. Comitê Brasileiro de Teste de Sensibilidade aos Antimicrobianos. Tabelas de pontos de corte para interpretação de CIMs e diâmetros de halos. 2023.

CHEN, Q. et al. Characterization of Two Macrolide Resistance-Related Genes in Multidrug-Resistant *Pseudomonas aeruginosa* Isolates. *Pol J Microbiol.*, v. 69, n. 3, p. 349-356, 2020.

CHONG, W.H. et al. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. *Infection.*, v. 11, p. 1-15. 11, 2021.

HU, Y., et al. Evaluation of IR Biotyper for carbapenem-resistant *Pseudomonas aeruginosa* typing and its application potential for the investigation of nosocomial infection. *Front Microbiol.* v.14, p. 1068872, 2023.

PEREIRA, R. M. M.; et al. Covid-19 e infecções relacionadas à assistência à saúde. *Revista Multidisciplinar em Saúde.* v. 2, n. 2, p. 43, 2021.

WHO. World Health Organization (WHO). COVID-19 Clinical management: living guidance. WHO: Genebra, 2020

ACKNOWLEDGMENT

This study was financed in part by CNPq: "Grant Chamada CNPq/MCTI/FNDCT N° 18/2021 - Faixa A - Grupos Emergentes N.º do Processo 407747/2021-4". This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. This project has been approved by the HFAG Research Ethics Committee and is registered on the Brazil Platform with CAAE code: 55303721.0.0000.5250.